دورية أكاديمية
أعرض في EDS

Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.

التفاصيل البيبلوغرافية
العنوان: Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.
المؤلفون: Finlay JB; Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham 27710, NC, USA., Ireland AS; Department of Pharmacology and Cancer Biology, Duke University, Durham 27710, NC, USA., Hawgood SB; Department of Pharmacology and Cancer Biology, Duke University, Durham 27710, NC, USA., Reyes T; Department of Pharmacology and Cancer Biology, Duke University, Durham 27710, NC, USA; Department of Oncological Sciences, University of Utah, Salt Lake City 84112, UT, USA., Ko T; Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham 27710, NC, USA., Olsen RR; Department of Oncological Sciences, University of Utah, Salt Lake City 84112, UT, USA., Abi Hachem R; Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham 27710, NC, USA., Jang DW; Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham 27710, NC, USA., Bell D; Division of Anatomic Pathology, City of Hope Comprehensive Cancer Center, Duarte 91010, CA, USA., Chan JM; Human Oncology and Pathogenesis Program, Memorial-Sloan Kettering Cancer Center, New York City 10065, NY, USA., Goldstein BJ; Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham 27710, NC, USA; Department of Neurobiology, Duke University, Durham 27710, NC, USA. Electronic address: bradley.goldstein@duke.edu., Oliver TG; Department of Pharmacology and Cancer Biology, Duke University, Durham 27710, NC, USA; Department of Oncological Sciences, University of Utah, Salt Lake City 84112, UT, USA. Electronic address: tgo@duke.edu.
المصدر: Cancer cell [Cancer Cell] 2024 Jun 10; Vol. 42 (6), pp. 1086-1105.e13. Date of Electronic Publication: 2024 May 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cambridge, Mass. : Cell Press, c2002-
مواضيع طبية MeSH: Small Cell Lung Carcinoma*/genetics , Small Cell Lung Carcinoma*/pathology , Small Cell Lung Carcinoma*/metabolism , Esthesioneuroblastoma, Olfactory*/genetics , Esthesioneuroblastoma, Olfactory*/pathology , Cell Lineage* , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Animals ; Mice ; Humans ; Basic Helix-Loop-Helix Transcription Factors/genetics ; Basic Helix-Loop-Helix Transcription Factors/metabolism ; Tumor Microenvironment ; Nose Neoplasms/genetics ; Nose Neoplasms/pathology ; Olfactory Mucosa/pathology ; Olfactory Mucosa/metabolism ; Disease Models, Animal ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism
مستخلص: The olfactory epithelium undergoes neuronal regeneration from basal stem cells and is susceptible to olfactory neuroblastoma (ONB), a rare tumor of unclear origins. Employing alterations in Rb1/Trp53/Myc (RPM), we establish a genetically engineered mouse model of high-grade metastatic ONB exhibiting a NEUROD1 + immature neuronal phenotype. We demonstrate that globose basal cells (GBCs) are a permissive cell of origin for ONB and that ONBs exhibit cell fate heterogeneity that mimics normal GBC developmental trajectories. ASCL1 loss in RPM ONB leads to emergence of non-neuronal histopathologies, including a POU2F3 + microvillar-like state. Similar to small-cell lung cancer (SCLC), mouse and human ONBs exhibit mutually exclusive NEUROD1 and POU2F3-like states, an immune-cold tumor microenvironment, intratumoral cell fate heterogeneity comprising neuronal and non-neuronal lineages, and cell fate plasticity-evidenced by barcode-based lineage tracing and single-cell transcriptomics. Collectively, our findings highlight conserved similarities between ONB and neuroendocrine tumors with significant implications for ONB classification and treatment.
Competing Interests: Declaration of interests TGO has a patent related to SCLC subtypes and a sponsored research agreement with Auron Therapeutics, serves on the scientific advisory board (SAB) for Lung Cancer Research Foundation, and as a consulting editor for Cancer Research and Genes & Development. BJG has interest in Rhino Therapeutics and is on the SAB for Smell and Taste Association of North America. J.C. has equity in Mirati Therapeutics and provision of services for Sonata Therapeutics. D.J. has consulted for Regeneron and ST Stent.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
References: Cell Syst. 2022 Sep 21;13(9):690-710.e17. (PMID: 35981544)
J Immunol. 2016 Dec 1;197(11):4493-4503. (PMID: 27799309)
Int J Cancer. 2019 Mar 1;144(5):1104-1114. (PMID: 30152518)
Nat Methods. 2022 Jan;19(1):41-50. (PMID: 34949812)
Adv Anat Pathol. 2009 Sep;16(5):322-31. (PMID: 19700942)
Cancer Res. 2010 May 15;70(10):3877-83. (PMID: 20406986)
Cancer Cell. 2023 Dec 11;41(12):2066-2082.e9. (PMID: 37995683)
Cancer Cell. 2019 Oct 14;36(4):385-401.e8. (PMID: 31564637)
Int Forum Allergy Rhinol. 2019 Sep;9(9):1054-1062. (PMID: 31251848)
Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18. (PMID: 34653364)
Nat Neurosci. 2007 Jun;10(6):720-6. (PMID: 17468753)
Oncogene. 2017 Aug 31;36(35):5075-5082. (PMID: 28459463)
Cancer Cell. 2021 Mar 8;39(3):346-360.e7. (PMID: 33482121)
J Thorac Oncol. 2022 Sep;17(9):1109-1121. (PMID: 35760287)
Ann Diagn Pathol. 2015 Jun;19(3):154-6. (PMID: 25892663)
Development. 2000 Jun;127(11):2323-32. (PMID: 10804175)
Nat Cell Biol. 2023 Sep;25(9):1346-1358. (PMID: 37591951)
Clin Cancer Res. 2018 Jan 15;24(2):360-369. (PMID: 29118061)
Stem Cell Reports. 2023 Nov 14;18(11):2283-2296. (PMID: 37832538)
Cell Rep. 2016 Aug 2;16(5):1259-1272. (PMID: 27452466)
Cancer Cell. 2017 Feb 13;31(2):270-285. (PMID: 28089889)
Cancer Res. 2023 Jan 18;83(2):301-315. (PMID: 36351060)
Nat Genet. 2012 Oct;44(10):1111-6. (PMID: 22941189)
Cancer. 1979 Sep;44(3):1087-94. (PMID: 383268)
Commun Biol. 2021 Mar 9;4(1):314. (PMID: 33750914)
Cancer Cell. 2011 Jun 14;19(6):754-64. (PMID: 21665149)
Bioinformatics. 2022 Apr 12;38(8):2169-2177. (PMID: 35157031)
J Hematol Oncol. 2023 Jun 24;16(1):66. (PMID: 37355629)
Laryngoscope. 2011 Aug;121(8):1687-701. (PMID: 21792956)
J Clin Invest. 2019 Jul 30;129(10):4492-4505. (PMID: 31361600)
Brain Pathol. 2004 Apr;14(2):158-63. (PMID: 15193028)
Mol Cancer Ther. 2022 Jun 1;21(6):986-998. (PMID: 35642431)
Sci Transl Med. 2022 Dec 21;14(676):eadd0484. (PMID: 36542694)
Nat Protoc. 2020 Mar;15(3):750-772. (PMID: 32051617)
Oncogene. 2022 Jan;41(1):138-145. (PMID: 34675406)
Cancers (Basel). 2023 Nov 10;15(22):. (PMID: 38001628)
Nat Commun. 2018 Sep 17;9(1):3787. (PMID: 30224629)
Sci Adv. 2021 Jan 29;7(5):. (PMID: 33514539)
PLoS One. 2012;7(5):e37029. (PMID: 22649506)
Nat Cancer. 2020 Apr;1:423-436. (PMID: 33521652)
Sci Adv. 2022 Dec 14;8(50):eabp8674. (PMID: 36516249)
Nature. 2016 Nov 10;539(7628):309-313. (PMID: 27806376)
Cell Rep Med. 2024 Feb 20;5(2):101381. (PMID: 38244540)
iScience. 2022 Dec 09;26(1):105760. (PMID: 36590163)
Nature. 2017 Jul 19;547(7663):311-317. (PMID: 28726821)
Genes Dev. 2016 Jun 1;30(11):1289-99. (PMID: 27298335)
Nat Protoc. 2009;4(7):1064-72. (PMID: 19561589)
PLoS Comput Biol. 2019 Oct 31;15(10):e1007343. (PMID: 31671086)
Nat Neurosci. 2020 Mar;23(3):323-326. (PMID: 32066986)
Science. 2022 Sep 9;377(6611):1180-1191. (PMID: 35981096)
Nat Rev Cancer. 2019 May;19(5):289-297. (PMID: 30926931)
J Physiol. 2023 May;601(9):1555-1572. (PMID: 37009787)
Genes Dev. 2018 Jul 1;32(13-14):915-928. (PMID: 29945888)
Am J Clin Pathol. 2004 Jul;122(1):100-5. (PMID: 15272537)
Cancer Cell. 2012 Mar 20;21(3):362-73. (PMID: 22439933)
Eur J Neurosci. 2013 Feb;37(4):572-82. (PMID: 23205840)
J Thorac Oncol. 2020 Dec;15(12):1823-1835. (PMID: 33011388)
Am J Surg Pathol. 2023 Feb 1;47(2):183-193. (PMID: 36253891)
Immunity. 2018 Oct 16;49(4):764-779.e9. (PMID: 30332632)
Genes Dev. 2021 Jun;35(11-12):847-869. (PMID: 34016693)
J Clin Oncol. 2023 Jun 1;41(16):2893-2903. (PMID: 36689692)
Nat Genet. 2012 Oct;44(10):1104-10. (PMID: 22941188)
Neurosurg Clin N Am. 2013 Jan;24(1):51-65. (PMID: 23174357)
Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482. (PMID: 29686080)
Dev Neurobiol. 2016 Mar;76(3):241-51. (PMID: 26016700)
Mol Cancer Ther. 2019 Nov;18(11):1926-1936. (PMID: 31649014)
Development. 2016 Dec 1;143(23):4394-4404. (PMID: 27789621)
Nature. 2018 Aug;560(7718):377-381. (PMID: 30069046)
Head Neck Pathol. 2009 Sep;3(3):252-9. (PMID: 20596981)
J Exp Med. 1985 May 1;161(5):1135-51. (PMID: 2580935)
World Neurosurg. 2020 Mar;135:e187-e193. (PMID: 31785431)
Mol Pharm. 2023 Nov 6;20(11):5543-5553. (PMID: 37788300)
Nat Biotechnol. 2020 May;38(5):586-599. (PMID: 32393914)
Mod Pathol. 2008 Jun;21(6):770-8. (PMID: 18408657)
Mol Oncol. 2020 Sep;14(9):1947-1965. (PMID: 32506804)
Nat Rev Genet. 2023 Aug;24(8):550-572. (PMID: 37002403)
Cell Stem Cell. 2017 Dec 7;21(6):775-790.e9. (PMID: 29174333)
Mod Pathol. 2023 May;36(5):100122. (PMID: 36841178)
Nature. 2017 May 18;545(7654):360-364. (PMID: 28489825)
Cancer Discov. 2021 Dec 1;11(12):3214-3229. (PMID: 34344693)
J Neurosci. 2003 Feb 1;23(3):807-15. (PMID: 12574409)
Mol Cancer Res. 2023 May 31;21(8):795-807. (PMID: 37255415)
Genes Dev. 2022 Mar 1;36(5-6):241-258. (PMID: 35318269)
Cancers (Basel). 2021 May 21;13(11):. (PMID: 34064009)
Cancer Res Commun. 2023 Jun 06;3(6):980-990. (PMID: 37377616)
Ann Surg. 1986 Mar;203(3):250-4. (PMID: 3954477)
J Virol. 1990 Aug;64(8):3988-91. (PMID: 2164606)
BMC Genomics. 2016 Aug 11;17(1):619. (PMID: 27515280)
Nat Commun. 2022 May 25;13(1):2929. (PMID: 35614043)
BMC Neurosci. 2014 Jan 16;15:13. (PMID: 24428937)
Ann Otol Rhinol Laryngol. 1977 Nov-Dec;86(6 Pt 1):760-5. (PMID: 596773)
Nature. 2015 Aug 6;524(7563):47-53. (PMID: 26168399)
Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7. (PMID: 12165452)
Semin Cancer Biol. 2011 Oct;21(4):267-75. (PMID: 21945349)
Science. 2021 Sep 03;373(6559):eabc1048. (PMID: 34516843)
Nature. 2018 Dec;564(7735):219-224. (PMID: 30518857)
Nucleic Acids Res. 2016 May 5;44(8):e71. (PMID: 26704973)
Cell. 2014 Oct 9;159(2):440-55. (PMID: 25263330)
Sci Transl Med. 2019 Mar 20;11(484):. (PMID: 30894499)
Cancer Cell. 2020 Jul 13;38(1):60-78.e12. (PMID: 32473656)
Cell Stem Cell. 2017 Jun 1;20(6):817-830.e8. (PMID: 28506465)
Mol Cell Biol. 1996 Apr;16(4):1794-804. (PMID: 8657155)
PLoS One. 2012;7(12):e51737. (PMID: 23284756)
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. (PMID: 27141961)
J Thorac Oncol. 2020 Sep;15(9):1507-1521. (PMID: 32470639)
Oncologist. 2017 Jul;22(7):834-842. (PMID: 28495808)
Laryngoscope Investig Otolaryngol. 2021 Jun 07;6(4):721-728. (PMID: 34401496)
Nat Commun. 2021 Jun 23;12(1):3880. (PMID: 34162872)
Curr Oncol Rep. 2023 Jan;25(1):11-18. (PMID: 36449116)
Head Neck. 1992 Nov-Dec;14(6):477-82. (PMID: 1468921)
J Neurosci. 1993 Jan;13(1):300-12. (PMID: 8423476)
EMBO Mol Med. 2014 Feb;6(2):212-25. (PMID: 24401838)
Cancer. 1979 Aug;44(2):564-79. (PMID: 383258)
Head Neck Pathol. 2018 Mar;12(1):22-30. (PMID: 29427030)
Nat Med. 2012 Sep;18(9):1423-8. (PMID: 22941275)
Nat Commun. 2021 Jun 7;12(1):3372. (PMID: 34099734)
J Comp Neurol. 2017 Mar 1;525(4):1034-1054. (PMID: 27560601)
Cell. 1993 Nov 5;75(3):463-76. (PMID: 8221886)
Mol Cancer Res. 2017 Nov;15(11):1551-1557. (PMID: 28775129)
J Clin Invest. 2022 Feb 15;132(4):. (PMID: 34990409)
Nature. 2018 Aug;560(7718):319-324. (PMID: 30069044)
J Neurocytol. 1979 Apr;8(2):197-213. (PMID: 469573)
PLoS One. 2018 Jan 11;13(1):e0191244. (PMID: 29324814)
Development. 1997 Apr;124(8):1611-21. (PMID: 9108377)
Lancet Oncol. 2017 Jan;18(1):42-51. (PMID: 27932068)
Cell Rep. 2018 Oct 16;25(3):811-821.e5. (PMID: 30332658)
معلومات مُعتمدة: R01 DC016859 United States DC NIDCD NIH HHS; U24 CA213274 United States CA NCI NIH HHS; U01 CA231844 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; F31 CA275295 United States CA NCI NIH HHS; F30 DC021348 United States DC NIDCD NIH HHS; P30 CA014236 United States CA NCI NIH HHS; UM1 CA239755 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: ASCL1; NEUROD1; POU2F3; RPM; SCLC; esthesioneuroblastoma; neuroendocrine; olfactory neuroblastoma; plasticity; tuft
المشرفين على المادة: 0 (Basic Helix-Loop-Helix Transcription Factors)
0 (Ascl1 protein, mouse)
0 (ASCL1 protein, human)
0 (Tumor Suppressor Protein p53)
تواريخ الأحداث: Date Created: 20240524 Date Completed: 20240611 Latest Revision: 20240801
رمز التحديث: 20240801
مُعرف محوري في PubMed: PMC11186085
DOI: 10.1016/j.ccell.2024.05.003
PMID: 38788720
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-3686
DOI:10.1016/j.ccell.2024.05.003